×

Cara Therapeutics to Present Data at the 8th World Congress on Itch

SHELTON, Conn., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will present a poster at the 8th World Congress on Itch, which will be held at the Nara Kasugano International Forum IRAKA in Nara, Japan. The poster will discuss positive data from Cara's Phase 2 study of I.V. CR845 in uremic pruritus, a chronic systemic itch condition in patients with renal failure, often receiving hemodialysis. CR845 is the Company's first-in-class peripherally-selective kappa opioid agonist currently in development for the treatment of acute and chronic pain and pruritus.

The poster details are as follows:

Title: "Decrease of Itch Intensity by CR845, a Novel Kappa Opioid Receptor Agonist"
Poster Number: PP24
Location: Nara Kasugano International Forum IRAKA, in 1F Meeting Room 1&2
Dates: Monday, September 28 from 15:00 to 16:00; Tuesday, September 29 from 14:30 to 15:30 Japan Standard Time
Presenters:

  • Robert Spencer, Ph.D., Senior Director, Research and Development, Cara Therapeutics
  • Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics; Assistant Professor, Department of Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine
  • Frédérique Menzaghi, Ph.D., Vice President, Research and Development, Cara Therapeutics

For more information on 8th World Congress on Itch, visit http://www.itchnara.jp/MeetingInformation.html.

About CR845

CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 490 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. In Q3'15, Cara initiated the first Phase 3 pivotal trial of I.V. CR845 in acute postoperative pain in patients undergoing a range of abdominal surgeries. In addition, an ongoing Phase 2 trial of an oral tablet formulation of CR845 for the treatment of osteoarthritis (OA) is expected to read out in Q4'15.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate to severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

CONTACT: INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 Jesse@sternir.com MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com

Source:Cara Therapeutics